Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last de...
Gespeichert in:
| Veröffentlicht in: | Journal of personalized medicine 2021-10, Vol.11 (11), p.1102, Article 1102 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 11 |
| container_start_page | 1102 |
| container_title | Journal of personalized medicine |
| container_volume | 11 |
| creator | Sutic, Maja Vukic, Ana Baranasic, Jurica Foersti, Asta Dzubur, Feda Samarzija, Miroslav Jakopovic, Marko Brcic, Luka Knezevic, Jelena |
| description | Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last decade and is no longer based on the "one-fits-all " paradigm or the general histological classification of non-small cell versus small cell lung cancer. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. Molecular biomarkers have emerged as valuable tools in the prognosis and prediction of therapy response. In this review, we discuss the relevant biomarkers used in the clinical management of lung tumors, from diagnosis to prognosis. We also discuss promising new biomarkers, focusing on non-small cell lung cancer as the most abundant type of lung cancer. |
| doi_str_mv | 10.3390/jpm11111102 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_journals_2602087526</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2604008540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-1274bcd6531e7e04892f3a62f16b276ddf3ac32f93e8d11087c46a714d817deb3</originalsourceid><addsrcrecordid>eNqNkVtvFCEUx4nR2Kb2yS9A4kuNHeU2wL6Y6NRbslaT6jNh4MzKugMrzLTx28u6m1p9kgfg5PzO9Y_QY0qec74gL9bbkf4-hN1Dx4yothGCyft3_kfotJQ1qUe3jEnyEB1xobkQrThG_UWwq5jKFNw5_pzBBzeFazjHNvpqp4MPvw5ptPk75IJDxJcpNlej3WxwB_VaznGFOxsdZHx2edUtu6f4o412BSPE6RF6MNhNgdPDe4K-vn3zpXvfLD-9-9C9WjaOazk1lCnROy9bTkEBEXrBBm4lG6jsmZLeV8txNiw4aF_n1coJaRUVXlPloecn6OU-73buR_Culs52Y7Y51M5_mmSD-dsTwzezStdGSyYEYTXB2SFBTj9mKJMZQ3F1QBshzcXU3YndEgWp6JN_0HWac6zj7ShWm2uZrNSzPeVyKiXDcNsMJWYnn7kjX6X1nr6BPg3FBagLvY2o8inGlZbtTknahclOIcUuzXH6U-h_Qvkv-aKqxw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2602087526</pqid></control><display><type>article</type><title>Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sutic, Maja ; Vukic, Ana ; Baranasic, Jurica ; Foersti, Asta ; Dzubur, Feda ; Samarzija, Miroslav ; Jakopovic, Marko ; Brcic, Luka ; Knezevic, Jelena</creator><creatorcontrib>Sutic, Maja ; Vukic, Ana ; Baranasic, Jurica ; Foersti, Asta ; Dzubur, Feda ; Samarzija, Miroslav ; Jakopovic, Marko ; Brcic, Luka ; Knezevic, Jelena</creatorcontrib><description>Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last decade and is no longer based on the "one-fits-all " paradigm or the general histological classification of non-small cell versus small cell lung cancer. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. Molecular biomarkers have emerged as valuable tools in the prognosis and prediction of therapy response. In this review, we discuss the relevant biomarkers used in the clinical management of lung tumors, from diagnosis to prognosis. We also discuss promising new biomarkers, focusing on non-small cell lung cancer as the most abundant type of lung cancer.</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm11111102</identifier><identifier>PMID: 34834454</identifier><language>eng</language><publisher>BASEL: Mdpi</publisher><subject>Biomarkers ; Biopsy ; Cancer therapies ; Chemotherapy ; Classification ; Disease ; General & Internal Medicine ; Health Care Sciences & Services ; Immunotherapy ; Life Sciences & Biomedicine ; Lung cancer ; Lymphatic system ; Medical imaging ; Medicine, General & Internal ; Morphology ; Mortality ; Mutation ; Non-small cell lung carcinoma ; Patients ; Precision medicine ; Prognosis ; Review ; Science & Technology ; Small cell lung carcinoma ; Tumors</subject><ispartof>Journal of personalized medicine, 2021-10, Vol.11 (11), p.1102, Article 1102</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>51</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000723786500001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c386t-1274bcd6531e7e04892f3a62f16b276ddf3ac32f93e8d11087c46a714d817deb3</citedby><cites>FETCH-LOGICAL-c386t-1274bcd6531e7e04892f3a62f16b276ddf3ac32f93e8d11087c46a714d817deb3</cites><orcidid>0000-0002-9857-4728 ; 0000-0002-3152-3563 ; 0000-0001-9971-9733 ; 0000-0002-9098-8416</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624402/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624402/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27928,27929,39262,53795,53797</link.rule.ids></links><search><creatorcontrib>Sutic, Maja</creatorcontrib><creatorcontrib>Vukic, Ana</creatorcontrib><creatorcontrib>Baranasic, Jurica</creatorcontrib><creatorcontrib>Foersti, Asta</creatorcontrib><creatorcontrib>Dzubur, Feda</creatorcontrib><creatorcontrib>Samarzija, Miroslav</creatorcontrib><creatorcontrib>Jakopovic, Marko</creatorcontrib><creatorcontrib>Brcic, Luka</creatorcontrib><creatorcontrib>Knezevic, Jelena</creatorcontrib><title>Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management</title><title>Journal of personalized medicine</title><addtitle>J PERS MED</addtitle><description>Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last decade and is no longer based on the "one-fits-all " paradigm or the general histological classification of non-small cell versus small cell lung cancer. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. Molecular biomarkers have emerged as valuable tools in the prognosis and prediction of therapy response. In this review, we discuss the relevant biomarkers used in the clinical management of lung tumors, from diagnosis to prognosis. We also discuss promising new biomarkers, focusing on non-small cell lung cancer as the most abundant type of lung cancer.</description><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Classification</subject><subject>Disease</subject><subject>General & Internal Medicine</subject><subject>Health Care Sciences & Services</subject><subject>Immunotherapy</subject><subject>Life Sciences & Biomedicine</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Medical imaging</subject><subject>Medicine, General & Internal</subject><subject>Morphology</subject><subject>Mortality</subject><subject>Mutation</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Prognosis</subject><subject>Review</subject><subject>Science & Technology</subject><subject>Small cell lung carcinoma</subject><subject>Tumors</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkVtvFCEUx4nR2Kb2yS9A4kuNHeU2wL6Y6NRbslaT6jNh4MzKugMrzLTx28u6m1p9kgfg5PzO9Y_QY0qec74gL9bbkf4-hN1Dx4yothGCyft3_kfotJQ1qUe3jEnyEB1xobkQrThG_UWwq5jKFNw5_pzBBzeFazjHNvpqp4MPvw5ptPk75IJDxJcpNlej3WxwB_VaznGFOxsdZHx2edUtu6f4o412BSPE6RF6MNhNgdPDe4K-vn3zpXvfLD-9-9C9WjaOazk1lCnROy9bTkEBEXrBBm4lG6jsmZLeV8txNiw4aF_n1coJaRUVXlPloecn6OU-73buR_Culs52Y7Y51M5_mmSD-dsTwzezStdGSyYEYTXB2SFBTj9mKJMZQ3F1QBshzcXU3YndEgWp6JN_0HWac6zj7ShWm2uZrNSzPeVyKiXDcNsMJWYnn7kjX6X1nr6BPg3FBagLvY2o8inGlZbtTknahclOIcUuzXH6U-h_Qvkv-aKqxw</recordid><startdate>20211027</startdate><enddate>20211027</enddate><creator>Sutic, Maja</creator><creator>Vukic, Ana</creator><creator>Baranasic, Jurica</creator><creator>Foersti, Asta</creator><creator>Dzubur, Feda</creator><creator>Samarzija, Miroslav</creator><creator>Jakopovic, Marko</creator><creator>Brcic, Luka</creator><creator>Knezevic, Jelena</creator><general>Mdpi</general><general>MDPI AG</general><general>MDPI</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9857-4728</orcidid><orcidid>https://orcid.org/0000-0002-3152-3563</orcidid><orcidid>https://orcid.org/0000-0001-9971-9733</orcidid><orcidid>https://orcid.org/0000-0002-9098-8416</orcidid></search><sort><creationdate>20211027</creationdate><title>Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management</title><author>Sutic, Maja ; Vukic, Ana ; Baranasic, Jurica ; Foersti, Asta ; Dzubur, Feda ; Samarzija, Miroslav ; Jakopovic, Marko ; Brcic, Luka ; Knezevic, Jelena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-1274bcd6531e7e04892f3a62f16b276ddf3ac32f93e8d11087c46a714d817deb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Classification</topic><topic>Disease</topic><topic>General & Internal Medicine</topic><topic>Health Care Sciences & Services</topic><topic>Immunotherapy</topic><topic>Life Sciences & Biomedicine</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Medical imaging</topic><topic>Medicine, General & Internal</topic><topic>Morphology</topic><topic>Mortality</topic><topic>Mutation</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Prognosis</topic><topic>Review</topic><topic>Science & Technology</topic><topic>Small cell lung carcinoma</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sutic, Maja</creatorcontrib><creatorcontrib>Vukic, Ana</creatorcontrib><creatorcontrib>Baranasic, Jurica</creatorcontrib><creatorcontrib>Foersti, Asta</creatorcontrib><creatorcontrib>Dzubur, Feda</creatorcontrib><creatorcontrib>Samarzija, Miroslav</creatorcontrib><creatorcontrib>Jakopovic, Marko</creatorcontrib><creatorcontrib>Brcic, Luka</creatorcontrib><creatorcontrib>Knezevic, Jelena</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sutic, Maja</au><au>Vukic, Ana</au><au>Baranasic, Jurica</au><au>Foersti, Asta</au><au>Dzubur, Feda</au><au>Samarzija, Miroslav</au><au>Jakopovic, Marko</au><au>Brcic, Luka</au><au>Knezevic, Jelena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management</atitle><jtitle>Journal of personalized medicine</jtitle><stitle>J PERS MED</stitle><date>2021-10-27</date><risdate>2021</risdate><volume>11</volume><issue>11</issue><spage>1102</spage><pages>1102-</pages><artnum>1102</artnum><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last decade and is no longer based on the "one-fits-all " paradigm or the general histological classification of non-small cell versus small cell lung cancer. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. Molecular biomarkers have emerged as valuable tools in the prognosis and prediction of therapy response. In this review, we discuss the relevant biomarkers used in the clinical management of lung tumors, from diagnosis to prognosis. We also discuss promising new biomarkers, focusing on non-small cell lung cancer as the most abundant type of lung cancer.</abstract><cop>BASEL</cop><pub>Mdpi</pub><pmid>34834454</pmid><doi>10.3390/jpm11111102</doi><tpages>27</tpages><orcidid>https://orcid.org/0000-0002-9857-4728</orcidid><orcidid>https://orcid.org/0000-0002-3152-3563</orcidid><orcidid>https://orcid.org/0000-0001-9971-9733</orcidid><orcidid>https://orcid.org/0000-0002-9098-8416</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2075-4426 |
| ispartof | Journal of personalized medicine, 2021-10, Vol.11 (11), p.1102, Article 1102 |
| issn | 2075-4426 2075-4426 |
| language | eng |
| recordid | cdi_proquest_journals_2602087526 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Biomarkers Biopsy Cancer therapies Chemotherapy Classification Disease General & Internal Medicine Health Care Sciences & Services Immunotherapy Life Sciences & Biomedicine Lung cancer Lymphatic system Medical imaging Medicine, General & Internal Morphology Mortality Mutation Non-small cell lung carcinoma Patients Precision medicine Prognosis Review Science & Technology Small cell lung carcinoma Tumors |
| title | Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T14%3A56%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic,%20Predictive,%20and%20Prognostic%20Biomarkers%20in%20Non-Small%20Cell%20Lung%20Cancer%20(NSCLC)%20Management&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Sutic,%20Maja&rft.date=2021-10-27&rft.volume=11&rft.issue=11&rft.spage=1102&rft.pages=1102-&rft.artnum=1102&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm11111102&rft_dat=%3Cproquest_webof%3E2604008540%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2602087526&rft_id=info:pmid/34834454&rfr_iscdi=true |